Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARAMOUNT: LCZ696 vs Valsartan in HFpEF
NCT00887588Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2009
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), sponsored by Novartis. Started Nov 2009; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00887588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887588.